

GUIDANCE ON INCREASING SUPPLIES OF PLASMA-DERIVED MEDICINAL PRODUCTS IN LOW- AND MIDDLE-INCOME COUNTRIES THROUGH FRACTIONATION OF DOMESTIC PLASMA







Guidance on increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma

ISBN 978-92-4-002181-5 (electronic version) ISBN 978-92-4-002182-2 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Guidance on increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout: L'IV Com Sàrl, Switzerland

CONTENTS

Prefa	acev
Ackr	nowledgements
List	of abbreviations and acronyms
Glos	sary
Exec	utive summary
Chap	oter 1. Background
1.1	Scope and objectives of the guidance
1.2	Blood: source of blood components for transfusion and purified protein products from plasma
	fractionation
1.3	PDMP therapies
1.4	Unmet needs for PDMPs
1.5	Wastage of recovered plasma
1.6	Urgent need for capacity-building in LMIC.
1.7	Optimal use of PDMPs
1.8	Concerted action in utilizing surplus protein products
Char	oter 2. Ensuring an adequate supply of plasma-derived medicinal products
2.1	Barriers to supply of suitable plasma for fractionation.
2.2	Requirement for a nationally organized, regulated and stably funded system
2.3	Establishment and enforcement of standards
2.4	Regulatory authorization of blood and plasma collection, testing and processing
2.5	GMP audits by the fractionator
2.6	Haemovigilance and pharmacovigilance
Char	nter 3. Strategies to obtain plasma for fractionation
31	Recovered and concurrent plasma
3.2	Source plasma.
Char	ater 4. Recruitment, retention and protection of blood and plasma donors
	Culturally consitive promotion of blood and plasma donation and social marketing
4.1 1/2	Culturally sensitive promotion of blood and plasma donaris on the specific value of plasma
4.2	and its products
4.3	Protection of donors' health and rights
Cha	en de la contra de la constitución
	Stendards for donor colorition
ס.ו בי	Standards for quality accured laboratory testing for evidence of transfusion transmissible infection 24
5.2 5.2	Standards for quality-assured laboratory testing for evidence of transfusion-transmissible infection
5.S	Good manufacturing practices (GMP) and quality management

iV GUIDANCE ON INCREASING SUPPLIES OF PLASMA-DERIVED MEDICINAL PRODUCTS IN LOW- AND MIDDLE-INCOME COUNTRIES THROUGH FRACTIONATION OF DOMESTIC PLASMA

Chapter 6. Country bilateral and regional cooperation			
Chap	Chapter 7. Production of plasma for fractionation		
7.1	Quality agreement between the blood establishment and the plasma fractionator		
7.2	Post-donation information and quality defects		
7.3	Stepwise approach for improving the supply of PDMPs		
Chap	ter 8. Economics of plasma collection and domestic manufacture of PDMPs		
8.1	Good manufacturing processes		
8.2	Cost considerations in plasma collection		
8.3	Cost consideration in domestic plasma manufacturing and associated risks.		
8.4	Additional financial considerations for domestic fractionation projects		
8.5	Contract manufacturing		
Chap	ter 9. Stepwise approach to domestic manufacture of plasma, plasma components and immune globulin		
conce	entrates with enhanced virus safety		
9.1	Motivation for local preparation of alternative products with enhanced virus safety pending		
	availability of PDMPs		
9.2	Stepwise measures to advance to local preparation of virus-inactivated plasma products		
Conclusion			
Refe	rences		

PREFACE

Plasma-derived medicinal products (PDMPs) play a major role in health care, including treatment for haemophilia, immune diseases, certain infections, and a variety of other serious conditions. A number of PDMPs are included in the WHO Model List of Essential Medicines, emphasizing their importance in the health system and the need to facilitate access to these products in all countries. However, unequal access globally to PDMPs, especially scarcity in many low-and middle-income countries (LMIC), leaves many patients with severe congenital and acquired disorders without adequate treatment. A major factor limiting the global availability of PDMPs is an inadequate supply of plasma meeting internationally recognized standards for fractionation. In response to this situation, the World Health Assembly in 2010 adopted resolution WHA63.12, which urges Member States "to take all the necessary steps to establish, implement and support nationally-coordinated, efficiently-managed and sustainable blood and plasma programmes according to the availability of resources, with the aim of achieving self-sufficiency, unless special circumstances preclude it".

Medical treatment using blood components rather than whole blood is gradually increasing in developing countries. This results in production of plasma in excess of clinical need. Such "surplus plasma" recovered from whole blood donations (recovered plasma) could be made available for fractionation into PDMPs to help address unmet patient needs. However, in LMIC, good manufacturing practice often is not in place, rendering recovered plasma unacceptable for fractionation, with considerable wastage of plasma as a result.

The WHO guidance on *Increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma* provides a strategic framework to assist Member States in increasing their volume of quality plasma for fractionation. The guidance was developed under the WHO Action Framework to Advance Universal Access to Safe, Effective and Quality-Assured Blood Products 2020–2023 to advance the objective of "functioning and efficiently managed blood services". This guidance is complementary to the WHO guidance on centralization of blood donation testing and processing, which assists Member States in deciding whether to centralize blood donation testing and provides practical guidance in that area. Centralization of blood donation processing can play an important role in increasing the availability of quality plasma for fractionation.

ACKNOWLEDGEMENTS

The development and publication of this guidance was coordinated by Yuyun Siti Maryuningsih (Team Lead, Blood and Other Products of Human Origin, Health Products Policy and Standards Department, WHO headquarters, Switzerland). The contribution of the following individuals is gratefully acknowledged.

The working group members who contributed to drafting the chapters: Noryati Abu Amin, National Blood Centre, Malaysia Jan M. Bult, Plasma Protein Therapeutics Association, the Netherlands Thierry Burnouf*, Graduate Institute of Biomedical Materials and Tissue Engineering, Taipei Medical University; informal WHO consultant for blood, France Ubonwon Charoonruangrit, former Director of National Blood Centre of the Thai Red Cross Society, Thailand Jicui Dong, WHO headquarters, Switzerland Jay Epstein*, Working Party for Global Blood Safety, International Society of Blood Transfusion, United States of America Peyman Eshghi, Iranian Blood Transfusion Organization, Islamic Republic of Iran Albert Farrugia, University of Western Australia, Australia Giuliano Grazzini, International Federation of Blood Donor Organizations, Monaco Alireza Khadem Broojerdi, WHO headquarters, Switzerland Giancarlo Liumbruno, Italian National Blood Centre, Rome, Italy Yuyun Siti Maryuningsih, WHO headquarters, Switzerland Micha Nuebling*, Paul Ehrlich Institute, Blood Regulator Network, Germany Christian Schaerer, Swissmedic, Blood Regulator Network, Switzerland Paul Strengers, International Plasma Fractionation Associations, Blood and IVD Track ECBS member, the Netherlands Jackie Thomson, South African National Blood Service, South Africa Junping Yu, WHO headquarters, Switzerland

* Core editing group members.

The individuals and organizations who reviewed and commented on the draft guidance document: Yetmgeta Eyayou Abdella, WHO Regional Office for the Eastern Mediterranean, Egypt Ranjeet Ajmani, PlasmaGen BioSciences, India

预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 24034